Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 10
2003 14
2004 16
2005 17
2006 26
2007 19
2008 29
2009 37
2010 53
2011 72
2012 65
2013 108
2014 149
2015 180
2016 175
2017 175
2018 200
2019 200
2020 211
2021 258
2022 276
2023 228
2024 251
2025 261
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,704 results

Results by year

Filters applied: . Clear all
Page 1
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K; PSMAfore Investigators. Morris MJ, et al. Among authors: wei xx. Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. Lancet. 2024. PMID: 39293462 Free PMC article. Clinical Trial.
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.
Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, Starzinski A, Wolters R, Arias-Badia M, Allaire K, Wu K, Gurunathan V, Valderrábano L, Wei XX, Miller RA, Van Allen EM, Fong L. Lyu A, et al. Among authors: wei xx. Nature. 2025 Jan;637(8048):1207-1217. doi: 10.1038/s41586-024-08290-3. Epub 2024 Dec 4. Nature. 2025. PMID: 39633050 Free PMC article.
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae.
Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, Cheng W, Li B, Li H, Lin W, Tian C, Zhao J, Han J, An D, Zhang Q, Wei H, Zheng M, Ma X, Li W, Chen X, Zhang Z, Zeng H, Ying S, Wu J, Yang R, Liu D. Yuan J, et al. Among authors: wei x. Cell Metab. 2019 Oct 1;30(4):675-688.e7. doi: 10.1016/j.cmet.2019.08.018. Epub 2019 Sep 19. Cell Metab. 2019. PMID: 31543403 Free article.
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K. Kuo PH, et al. Among authors: wei xx. Radiology. 2024 Aug;312(2):e233460. doi: 10.1148/radiol.233460. Radiology. 2024. PMID: 39162634 Free PMC article. Clinical Trial.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Fizazi K, et al. Among authors: wei xx. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. Lancet Oncol. 2023. PMID: 37269841 Free PMC article. Clinical Trial.
2,704 results